Latest Bare-metal stent Stories

CHICAGO, March 14, 2013 /PRNewswire/ -- Zacks.com announces the list of stocks featured in the Analyst Blog. Every day the Zacks Equity Research analysts discuss the latest news and events impacting stocks and the financial markets. Stocks recently featured in the blog include Boston Scientific (NYSE:BSX), Abbott Laboratories (NYSE:ABT), Cyberonics Inc. (Nasdaq:CYBX), Given Imaging. (Nasdaq:GIVN) and Aflac Inc. (NYSE:AFL). (Logo: http://photos.prnewswire.com/prnh/20101027/ZIRLOGO)...

SINGAPORE, Jan. 28, 2013 /PRNewswire/ -- Biosensors International Group, Ltd. ("Biosensors" or the "Company", Bloomberg: BIG SP; Reuters: BIOS.SI; SGX: B20), a developer, manufacturer and marketer of innovative medical devices, today announced CE Mark approval for its polymer-free drug-coated stent (DCS), BioFreedom(TM). BioFreedom represents the latest development in Biosensors' stent technology, featuring a micro-structured abluminal surface which permits the controlled release of...

SINGAPORE, Nov. 7, 2012 /PRNewswire/ -- Biosensors International Group, Ltd. ("Biosensors" or the "Company", Bloomberg: BIG:SP; Reuters: BIOS.SI; SGX: B20), a developer, manufacturer and marketer of innovative medical devices, today announced financial results for the second quarter of fiscal year 2013 (Q2 FY13) and the fiscal six months ended 30 September 2012 (H1 FY13). Q2 FY13 and Recent Highlights: Total revenue of US$79.8 million, representing 28% year-on-year growth...

DURHAM, N.C., Nov. 6, 2012 /PRNewswire/ -- Micell Technologies, Inc. today announced that the United States Patent and Trademark Office (USPTO) has issued a patent covering the company's surface and polymer modification technology. This intellectual property protection is related to Micell's investigational MiStent(®) Sirolimus Eluting Absorbable Polymer Coronary Stent System (MiStent SES(TM)), as well as potential additional biomedical products. The patent rights are assigned to...

Results of the MASTER trial reported at TCT 2012 and published in JACC A clinical trial found that the use of a next generation, micronet, mesh-covered stent demonstrated improved restoration of blood flow to heart tissue, compared to the use of either bare-metal or drug-eluting stents in heart attack patients undergoing angioplasty. Results of the MASTER trial were presented today at the 24th annual Transcatheter Cardiovascular Therapeutics (TCT) scientific symposium and will appear in...

DURHAM, N.C., Oct. 23, 2012 /PRNewswire/ -- Micell Technologies, Inc. today announced positive data from two clinical studies of its investigational MiStent(®) Sirolimus Eluting Absorbable Polymer Coronary Stent System (MiStent SES(TM)), a thin-strut drug-eluting stent distinguished by a rapid-absorbing drug/polymer coating designed to control drug release. Eighteen-month outcomes from the DESSOLVE I trial, and nine-month data supporting all study endpoints in the DESSOLVE II...

DURHAM, N.C., Oct. 16, 2012 /PRNewswire/ -- Micell Technologies, Inc. today announced that data from clinical studies of its investigational MiStent(®) Sirolimus Eluting Absorbable Polymer Coronary Stent System (MiStent SES(TM)) will be presented at the 24th Annual Transcatheter Cardiovascular Therapeutics (TCT) scientific symposium to be held in Miami, Fla. on October 22 - 26, 2012. David Kandzari, M.D., Director of Interventional Cardiology and Chief Scientific Officer for the...

NATICK, Mass., June 4, 2012 /PRNewswire/ -- The U.S. Food and Drug Administration (FDA) has provided Boston Scientific Corporation (NYSE: BSX) regulatory approval of 32 mm and 38 mm lengths for the PROMUS Element((TM)) Plus Everolimus-Eluting Platinum Chromium Coronary Stent System, the company's next-generation drug-eluting stent (DES) technology. The PROMUS Element Stent is built on an innovative platinum chromium (PtCr) platform with the market-leading everolimus drug...

NATICK, Mass., May 14, 2012 /PRNewswire/ -- Boston Scientific Corporation (NYSE: BSX) announces CE Mark and European market launch of the Innova(TM) Self-Expanding Bare-Metal Stent System, which is designed to treat peripheral vascular lesions in arteries above the knee, specifically the superficial femoral artery (SFA) and proximal popliteal artery (PPA). The company plans to launch the product immediately in Europe and other CE Mark countries. "Treating arteries above the...

Post-PASSION trial analysis confirms no major adverse cardiac events New research confirms thrombus aspiration (TA) during percutaneous coronary intervention (PCI) in patients with acute ST-segment elevation myocardial infarction (STEMI) provides long-term outcomes similar to conventional intervention with bare-metal or drug-eluting stents. Findings published in a special STEMI-focused issue of Catheterization and Cardiovascular Interventions, a journal of the Society for Cardiovascular...